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DownPurpose: EphA2 overexpression is frequently observed in endometrial cancers and is predictive of poor
clinical outcome. Here, we use an antibody drug conjugate (MEDI-547) composed of a fully human
monoclonal antibody against both human and murine EphA2 (1C1) and the tubulin polymerization
inhibitor monomethylauristatin F.
Experimental Design: EphA2 expression was examined in endometrial cancer cell lines by Western
blot. Specificity of MEDI-547 was examined by antibody degradation and internalization assays. Viability
and apoptosis were investigated in endometrial cancer cell lines and orthotopic tumor models.
Results: EphA2 was expressed in the Hec-1A and Ishikawa cells but was absent in the SPEC-2 cells.
Antibody degradation and internalization assays showed that the antibody drug conjugate decreased
EphA2 protein levels and was internalized in EphA2-positive cells (Hec-1A and Ishikawa). Moreover,
in vitro cytotoxicity and apoptosis assays showed that the antibody drug conjugate decreased viability
and increased apoptosis of Hec-1A and Ishikawa cells. In vivo therapy experiments in mouse orthotopic
models with this antibody drug conjugate resulted in 86% to 88% growth inhibition (P < 0.001) in the
orthotopic Hec-1A and Ishikawa models compared with controls. Moreover, the mice treated with this
antibody drug conjugate had a lower incidence of distant metastasis compared with controls. The anti-
tumor effects of the therapy were related to decreased proliferation and increased apoptosis of tumor and
associated endothelial cells.
Conclusions: The preclinical data for endometrial cancer treatment using MEDI-547 show substantial
antitumor activity. Clin Cancer Res; 16(9); 2562–70. ©2010 AACR.Endometrial cancer is the most common gynecologic
malignancy and the fourth most common cancer in North
American and European women (1). Overall prognosis for
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on Decembclincancerres.aacrjournals.org loaded from with early-stage disease that is confined to the uterus at
the time of hysterectomy, leading to 5-year survival rates
of >70% (2). Unfortunately, women with recurrent or
advanced-stage disease have amuch poorer prognosis, with
a median survival of ∼12 months (3). The mainstay of
treatment for these women remains systemic therapy in
the form of hormonal agents or cytotoxic chemotherapy,
and whereas some responses have been documented, the
treatment programs are associated with intolerable side
effects and infrequent durable remission (4). Therefore, new-
er and more effective targeted therapies are urgently needed.
Efforts to improve the cytotoxic action of monoclonal
antibodies (mAb) and consequently their therapeutic ef-
fectiveness have focused on conjugates with highly toxic
substances, including radioisotopes and cytotoxic agents
(5). These conjugates can deliver a toxic load selectively
to the tumor site while generally sparing normal tissues.
To date, just two radioimmunoconjugates (ibritumomab
tiuxetan and tositumomab) and one chemoimmunocon-
jugate (gemtuzumab ozogamicin) have been approved
in the United States for limited use in refractory hema-
tologic cancers (6–8). Thus, mAb conjugates can be a
viable approach to killing tumor cells in hematologic
malignancies.h. 
er 23, 2013. © 2010 American Association for Cancer
Translational Relevance
EphA2 overexpression is frequently observed in en-
dometrial cancers and is predictive of poor clinical out-
come. Due to the relatively low expression in normal
adult tissues, EphA2 may represent a novel target for
molecularly targeted delivery of cytotoxic agents. Here,
we use an antibody drug conjugate (MEDI-547) com-
posed of a fully human monoclonal antibody against
both human and murine EphA2 (1C1) and the tubulin
polymerization inhibitor monomethylauristatin F.
MEDI-547 specifically bound to and was internalized
by EphA2-positive cells (Hec-1A and Ishikawa). More-
over, in vitro cytotoxicity and apoptosis assays showed
that MEDI-547 decreased viability and increased apo-
ptosis of Hec-1A and Ishikawa cells. In vivo therapy
experiments in mouse orthotopic models with MEDI-
547 resulted in significant growth inhibition in the
orthotopic Hec-1A and Ishikawa models.
EphA2 Antibody Drug Conjugate in Endometrial Carcinoma
Published OnlineFirst April 13, 2010; DOI: 10.1158/1078-0432.CCR-10-0017 The Eph receptors are the largest family of tyrosine ki-
nases and are divided into two subclasses based on inter-
action with their ligands, ephrin-A and ephrin-B (9). There
is growing evidence that several Eph receptors play critical
roles in cancer development and progression (10). More-
over, high expression of EphA2 was detected in human en-
dometrial carcinoma, which was significantly associated
with poor clinical outcome (11). In normal adult tissues,
EphA2 expression is either absent or present at low levels
in only a few epithelial tissues (9); therefore, EphA2 could
be an ideal therapeutic target in patients with advanced or
recurrent endometrial cancer.
Recently, an EphA2 targeted antibody drug conjugate
with a fully human mAb (1C1) has been developed,
which selectively binds both the human and rodent
EphA2 receptor. This antibody is conjugated to the micro-
tubule inhibitor monomethylauristatin F (MMAF) using a
stable maleimidocaproyl (mc) linker (MEDI-547; refs.
12–14). The purpose of our study was to determine the bi-
ological activity of this antibody drug conjugate in endome-
trial cancer using orthotopic endometrial cancer models.Materials and Methods
Cell lines and cultures. Endometrial cell lines Ishikawa,
Hec-1A, and KLE were maintained and propagated in
MEM (Ishikawa), McCoy's 5A (Hec-1A), and 1:1 DMEM:
F12 (KLE) media supplemented with 10% fetal bovine se-
rum and 1% penicillin (Life Technologies) at 37°C (15).
The human papillary serous endometrial carcinoma cell
line SPEC-2 was maintained in a 1:1 mixture of DMEM
and Ham's F-12 medium supplemented with 10%
fetal bovine serum, sodium pyruvate, nonessential
amino acids, L-glutamine, and a 2-fold vitamin solutionwww.aacrjournals.org
Researc
on Decembclincancerres.aacrjournals.org Downloaded from (Life Technologies Laboratories; ref. 16). The Ishikawa
and Hec-1A cell lines were obtained from Dr. Russell
Broaddus (M.D. Anderson Cancer Center), and SPEC-2
was from Dr. Isaiah J. Fidler (M.D. Anderson Cancer Cen-
ter). The KLE cell line was obtained from the American
Type Culture Collection. All experiments were conducted
at 70% to 80% confluent cultures. Before in vivo injection,
cells were trypsinized, centrifuged at 1,000 rpm for 7 min-
utes at 4°C, washed twice with HBSS, and resuspended in
HBSS for intrauterine injections. Both cell lines were tested
and found to be negative for murine antigen reactivity and
Mycoplasma species before injection into mice.
Antibodies and antibody drug conjugates. 1C1 (fully hu-
man mAb recognizing both human and murine EphA2),
control IgG-mcMMAF (nonbinding specific IgG mAb con-
jugated to MMAF via the mc linker), and MEDI-547 (1C1
conjugated to MMAF via the mc linker) were provided by
MedImmune, LLC. The antibody description and the de-
tails of the conjugation reaction have been described pre-
viously (12).
Western blot. The preparation of cultured cell lysates has
been described previously (17, 18). Briefly, protein con-
centrations were determined using a bicinchoninic acid
protein assay reagent kit (Pierce Biotechnology), and ali-
quots of 20 μg protein were subjected to gel electrophore-
sis on 10% SDS-polyacrylamide gels. The proteins were
then transferred to a nitrocellulose membrane (Millipore)
and then incubated overnight at 4°C with primary anti-
body (mouse anti-human/mouse EphA2 mAb; clone D7,
Upstate) after washing with TBST. Themembranes were in-
cubated with 1 μg/mL horseradish peroxidase–conjugated
horse anti-mouse IgG (Amersham). Horseradish peroxi-
dase was visualized by use of an enhanced chemilumines-
cence detection kit (Pierce; refs. 18, 19).
Antibody internalization. Procedures for antibody inter-
nalization after treatment with MEDI-547 in Hec-1A and
Ishikawa cells were done as described previously (12).
Briefly, viable cells (0.5 × 106) were aliquoted into wells
of a 96-well plate in 100 μL of growth media. The cells
were centrifuged at 1,500 rpm for 5 minutes and labeled
with primary antibody drug conjugates by resuspension in
100 μL PBS containing 5 μg of MEDI-547 or control IgG-
mcMMAF and incubated for 30 minutes at 4°C. Cells were
then washed twice with PBS, and cell surface–bound pri-
mary antibody drug conjugates were allowed to internalize
by resuspending the cells in 100 μL of growth media and
incubation at 37°C/5% CO2 for 30 minutes or on ice as
negative control. Subsequent to internalization, cells were
fixed (4% paraformaldehyde, 20 minutes at room temper-
ature) and permeabilized (0.5% Triton X-100, 5 minutes
at room temperature). Cells were then labeled with se-
condary AlexaFluor 488 goat anti-human IgG antibody
(Biosource) by resuspension in 100 μL PBS + 2% fetal bo-
vine serum containing 1 μg of secondary antibody and in-
cubated for 30 minutes at 4°C (12).
Cytotoxicity assay. The cytotoxic effects of 1C1, control
IgG-mcMMAF, and MEDI-547 were determined by the
MTT uptake assay as described previously (20).Clin Cancer Res; 16(9) May 1, 2010 2563
h. 
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apoptotic cells was assessed at three time points (24, 48,
and 72 hours) using the Annexin V–FITC apoptosis detec-
tion kit-1 (BD Pharmingen) according to the manufac-
turer's protocol. Briefly, Hec-1A and Ishikawa cells were
washed twice in PBS, and the pellet was resuspended in
Annexin V binding buffer at a concentration of 106 cells/
mL. Annexin V FITC and propidium iodide were added
(5 μL to each per 105 cells). Samples were mixed gently
and incubated for 15 min at room temperature in the dark
before fluorescence-activated cell sorting analysis.
Animal care and orthotopic implantation of tumor cells.
Female athymic mice (NCr-nu) were purchased from the
National Cancer Institute-Frederick Cancer Research and
Development Center. The mice were housed and main-
tained under specific pathogen-free conditions in facilities
approved by the American Association for Accreditation
of Laboratory Animal Care and in accordance with the
current regulations and standards of U.S. Department ofClin Cancer Res; 16(9) May 1, 2010
Researc
on Decembclincancerres.aacrjournals.org Downloaded from Agriculture, U.S. Department of Health and Human Ser-
vices, and NIH. All studies were approved and supervised
by the University of Texas M.D. Anderson Cancer Center
Institutional Animal Care and Use Committee. The mice
used in these experiments were 8 to 12 weeks old. To pro-
duce tumors, Hec-1A and Ishikawa cells (both 4.0 × 106
per 50 μL HBSS; Life Technologies Invitrogen; ref. 15) or
SPEC-2 cells (2.0 × 106 per 50 μL HBSS; ref. 16) were
injected into the mice. Before injection, mice were anesthe-
tized with isoflurane inhalation (Baxter) and a 0.5-cm in-
cision was made in the right lower flank to optimize
exposure to the right uterine horn. The distal portion of
the horn was then identified and pulled to the incision
for exposure. A single-cell suspension of 50 μL was then
injected into the lumen of the uterine horn. The injection
site was closely monitored during and following injection
to ensure that no spillage occurred into the peritoneal cav-
ity (15). The incision was then closed with staples. Mice
(n = 10 per group) were monitored daily for adverse effectsFig. 1. EphA2 expression in endometrial cancer cell lines and the assessment of antibody degradation and internalization of EphA2 antibody drug
conjugates. A, EphA2 expression in several endometrial cancer cells was assessed by Western blot. B, effect of 1C1 or MEDI-547 on EphA2 levels in
Hec-1A and Ishikawa cells was assessed by Western blot. Cells were treated with PBS (control), 1C1, control IgG-mcMMAF, or MEDI-547 (each at
100 ng/mL) for 48, 72, or 96 hours. C, internalization of EphA2 on Hec-1A and Ishikawa cells treated with MEDI-547. Cells were immunostained for EphA2
with PBS containing MEDI-547 (5 μg) and then incubated for 20 minutes at 4°C. The experiment was done thrice.Clinical Cancer Research
h. 
er 23, 2013. © 2010 American Association for Cancer
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Published OnlineFirst April 13, 2010; DOI: 10.1158/1078-0432.CCR-10-0017 of therapy and were sacrificed when any of the mice
seemed moribund. Total body weight, tumor incidence
and mass, and the number and location of tumor nodules
were recorded. Tumors were fixed in formalin and embed-
ded in paraffin or snap frozen in optimal cutting tempera-
ture media in liquid nitrogen.
Therapy for established endometrial tumors in nude mice.
The antibody drug conjugate was dosed using 3 mg/kg i.p.
injections weekly (14). Therapy experiments were
designed using human endometrial cancer cell lines
Hec-1A, Ishikawa, and SPEC-2. Following cell line injec-
tion, mice were randomized into four treatment groups:
(a) control, 200 μL PBS (i.p., weekly); (b) 1C1, 3 mg/kg
in 200 μL PBS (i.p., weekly); (c) control IgG-mcMMAF,
3 mg/kg in 200 μL PBS (i.p., weekly); and (d) MEDI-www.aacrjournals.org
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initiated 2 weeks following cell line injection (15). Mice
weremonitored for adverse effects and sacrificed by cervical
dislocation 6 to 7 weeks following initiation of treatment.
Immunohistochemistry. Procedures for immunohisto-
chemical analysis of EphA2 and proliferating cell nuclear
antigen (PCNA)were done as described previously (18, 21).
Immunofluorescence double staining for CD31 and termi-
nal deoxynucleotidyl transferase-mediated nick end labeling.
Frozen tissues were used for CD31/terminal deoxynucleo-
tidyl transferase-mediated nick end labeling (TUNEL) im-
munofluorescence double staining as described previously
(22). The quantification of apoptotic endothelial cells was
calculated by the number of apoptotic endothelial cells in
10 random fields at ×200 magnification.Fig. 2. Effect of MEDI-547 on in vitro tumor cell viability. A, viability of cultured Hec-1A cells after treatment with 1C1 or antibody drug conjugates
(IgG-mcMMAF or MEDI-547). Viability was assessed with the MTT assay at 48, 72, or 96 hours after treatment with 1C1, control IgG-mcMMAF, or
MEDI-547, respectively, at 10 to 50,000 ng/mL. Results were confirmed with duplicate experiments. Bars, SEM. B, apoptotic cells as detected by flow
cytometry. Induction of apoptosis in Hec-1A cells after treatment with 500 ng/mL of PBS (control), 1C1, IgG-mcMMAF, or MEDI-547 for 24 to 72 hours.
Apoptosis was examined by the Annexin V and propidium iodide dual staining assay, as detected by flow cytometry. The ratio of positive-staining cells was
calculated and presented as mean ± SD. *, P < 0.01. Each experiment was preformed twice with similar results in both experiments.Clin Cancer Res; 16(9) May 1, 2010 2565
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Published OnlineFirst April 13, 2010; DOI: 10.1158/1078-0432.CCR-10-0017 Statistical methods. For animal experiments, 10micewere
assigned per treatment group. This sample size gave 80%
power to detect a 50% reduction in tumor weight at a 5%
level of statistical significance. Mouse and tumor weights
and the number of tumor nodules for each groupwere com-
pared using ANOVA and post-hoc analysis (Dunnett's
method). Normality was tested by Kolmogrov-Smirnov test.
Variables not meeting the criteria for normality were inter-
rogated using the Mann-Whitney rank-sum test using the
Statistical Package for the Social Sciences (SPSS, Inc.). A
P value of <0.05 was considered statistically significant.
Results
EphA2 degradation and internalization of MEDI-547.
Among the endometrial cancer cell lines tested, EphA2
protein expression was detected in the KLE, Hec-1A, andClin Cancer Res; 16(9) May 1, 2010
Researc
on Decembclincancerres.aacrjournals.org Downloaded from Ishikawa cells but was absent in the SPEC-2 cells (Fig.
1A). Because agonist antibodies can cause internalization
and degradation of EphA2, we first asked whether MEDI-
547 would affect EphA2 levels. EphA2 expression showed
the greatest decrease following treatment with 1C1 or
MEDI-547 compared with control (PBS) or control IgG-
mcMMAF in Hec-1A and Ishikawa cells at 48 hours after
treatment and gradual return of expression by 96 hours
(Fig. 1B). After stimulation of the EphA2 receptor on
Hec-1A and Ishikawa cells with MEDI-547 for 20 minutes,
antibody internalization was detected by immunofluores-
cence (Fig. 1C). These results were not observed in the
EphA2-negative SKMel 28 cells (data not shown).
In vitro sensitivity of endometrial cancer cells to MEDI-
547. We next tested the effect of MEDI-547 on in vitro
viability of the EphA2-positive Hec-1A and Ishikawa
cells. The effect of MEDI-547 was tested at doses rangingh. 
er 23, 2013. © 2010 AmericaFig. 3. Effect of MEDI-547 therapy
on endometrial cancer growth.
Mice inoculated with Hec-1A (A),
Ishikawa (B), or SPEC-2 (C) cells
received PBS (control), 1C1,
control IgG-mcMMAF, or
MEDI-547 (each at 3 mg/kg) after
2 weeks following cell line injection.
Animals from all groups were
sacrificed when control animals
became moribund (5-6 weeks after
initiating therapy depending on
the cell line used). All tumors were
harvested; mean tumor weight and
its distribution were recorded.
Columns, mean tumor weights for
each samples group; bars, SD.
*, P < 0.01.Clinical Cancer Research
n Association for Cancer
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Published OnlineFirst April 13, 2010; DOI: 10.1158/1078-0432.CCR-10-0017 from 10 to 50,000 ng/mL. In the Hec-1A cells compared
with controls (either 1C1 or control IgG-mcMMAF),
growth was significantly inhibited by MEDI-547 in a
dose-dependent manner (Fig. 2A). Similar results were
noted with the Ishikawa cells (Fig. S1A). But there was
no effect in EPhA2-negative SPEC-2 cells (Supplementary
Fig. S2). Given the decrease in cell viability following
treatment, we next asked whether the effects were apop-
totic in nature. Treatment with MEDI-547 showed a sig-
nificant increase in apoptosis compared with treatment
with the controls in the Hec-1A (P < 0.05; Fig. 2B) and
Ishikawa (P < 0.05, Fig. S1B) cells.
In vivo tumor growth inhibition of MEDI-547–treated
endometrial carcinoma.On the basis of the observed effects
for cytotoxicity and apoptosis on endometrial cancer cells,
we next did several in vivo experiments using an orthotopicwww.aacrjournals.org
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therapeutic efficacy of MEDI-547. Mice injected with either
Hec-1A or Ishikawa were assigned to one of four groups
(n = 10 mice per group): (a) PBS; (b) 1C1, 3 mg/kg weekly;
(c) control IgG-mcMMAF, 3 mg/kg weekly; or (d) MEDI-547,
3 mg/kg weekly. Following 5 to 6 weeks of therapy, the
mice were sacrificed and necropsies were done. Prolonged
MEDI-547 therapy led to a significant reduction in tumor
growth in the Hec-1A and Ishikawa models compared
with control (PBS), 1C1, or control IgG-mcMMAF (each
P < 0.01; Fig. 3A and B, respectively). We next asked
whether the MEDI-547 has antiangiogenic effects in vivo
because it also recognizes murine EphA2 (18). To address
this question, we used the EphA2-negative SPEC-2 cells
(Fig. 1A). The tumor vasculature is known to express
higher EphA2 levels compared with normal endothelialFig. 4. Tumor distribution of Hec1A mouse model. A, MEDI-547 treated group had relatively less loci of distant metastasis, especially mesentery, liver,
and para-aortic nodes. Histologic slides showed that the endometrial cancer had developed from the uterine cavity (B) and showed ovarian metastasis
(arrowheads; C).Clin Cancer Res; 16(9) May 1, 2010 2567
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547–treated group was lower than the other groups, the
difference did not reach statistical significance (Fig. 3C).
No obvious signs of toxicity were observed in the treat-
ment groups (i.e., body weight loss).
In the Hec-1A model, metastases developed to the pel-
vis, omentum, mesentery, porta hepatis, perisplenic area,
liver, para-aortic lymph nodes, and diaphragm. We also
examined whether MEDI-547 therapy could reduce meta-
static spread. When we assessed the number of metastases
by site (n = 10 per group), treatment with MEDI-547 re-
sulted in a substantially lower frequency of metastases
compared with the 1C1 or control IgG-mcMMAF con-
trols, especially in mesentery, liver, and para-aortic nodes
(Fig. 4A). And in a representative sample, histologic slides
showed that the endometrial cancer had developed from
the uterine cavity (Fig. 4B) and showed ovarian metastasis
(Fig. 4C).
Effect of MEDI-547 on cell proliferation, apoptosis, and
antiangiogenesis. To determine potential mechanisms un-
derlying the antitumor activity of MEDI-547 treatment, we
examined the effect of MEDI-547 therapy on tumor cell
proliferation by using PCNA staining. In the Hec-1A
model, tumor cell proliferation was significantly reduced
following MEDI-547 treatment compared with controlsClin Cancer Res; 16(9) May 1, 2010
Researc
on Decembclincancerres.aacrjournals.org Downloaded from (P < 0.05; Fig. 5). Similar results were noted in the
Ishikawa model (P < 0.05; Supplementary Fig. S3). TUNEL
staining revealed that MEDI-547 treatment also resulted in
significantly increased apoptosis in the Hec-1A (P < 0.05;
Fig. 5) and Ishikawa (P < 0.05; Supplementary Fig. S3)
models. To test for potential direct effects on the tumor
vasculature, we did dual immunofluorescence (CD31/TU-
NEL) staining following short-term treatment. There was a
significant increase in endothelial cell apoptosis in the
MEDI-547 group in both Hec-1A (P < 0.05; Fig. 5) and
Ishikawa (P < 0.05; Supplementary Fig. S3) models. These
data suggest that the MEDI-547 therapy exerts antitumor
effects by both direct and indirect effects on tumor growth.
Moreover, in the EphA2-negative SPEC-2 model, whereas
tumor cell PCNA and TUNEL expression was not signifi-
cantly lower, there was significantly greater endothelial
cell apoptosis with MEDI-547 treatment (P < 0.05; data
not shown).
Discussion
The identification of effective therapies for the treatment
of endometrial cancer is critical. Although current thera-
pies have included various chemotherapeutics, recent
radiation and hormonal therapy reports suggest thatFig. 5. In vivo effects of MEDI-547 on proliferation and apoptosis of tumor or endothelial cells in the Hec-1A model. A, tumor sections were stained
with PCNA to reveal tumor cell proliferation. PCNA-positive cells were counted and graphed. *, P < 0.05. B, tumor sections were stained with Hoechst (blue)
and TUNEL (green) using double immunofluorescence staining. The tumor cells undergoing apoptosis show green fluorescence. C, tumor sections were
stained with CD31 (red) and TUNEL (green) using double immunofluorescence staining. Colocalization of endothelial cells undergoing apoptosis shows
yellow fluorescence. D, EphA2 expression in the tumor tissues taken at the time of sacrifice (3 days after injection of last dose) was assessed by
immunohistochemistry. Inset in PBS panel represents a negative control. Error bars, SD. *, P < 0.05.Clinical Cancer Research
h. 
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Published OnlineFirst April 13, 2010; DOI: 10.1158/1078-0432.CCR-10-0017 biologics, such as bevacizumab or cetuximab, may be
efficacious in endometrial cancer (23, 24). The EphA2
antibody drug conjugate (MEDI-547) selectively delivers
a tubulin polymerization inhibitor to EphA2-expressing
tumors resulting in cell death and the inhibition of tumor
growth.
The key findings from this study are that MEDI-547
effectively inhibits uterine cancer growth in orthotopic
xenograft tumor models without overt signs of toxicity
(i.e., weight loss). Our data indicate that MEDI-547 is
internalized by the EphA2-positive cells, resulting in
cytotoxicity. Moreover, MEDI-547 shows therapeutic
activity in orthotopic animal models by both direct and
possibly indirect effects on tumor cells.
The microtubule inhibitors paclitaxel and docetaxel, in
combination therapy, are used to treat endometrial cancer
patients and have shown some promise. We would antici-
pate that MEDI-547 treatment may be useful for endome-
trial cancer patients by delivery of themicrotubule inhibitor
(MMAF) to the tumor. Derivatives of MMAF have been suc-
cessfully used as potent cytotoxic agents that are delivered
by conjugated antibodies (25). Various linker and aurista-
tin combinations can specifically kill tumor cells after inter-
nalization through cell surface antigens, such as CD30
(26), CD70 (27), and CD79 (28). The covalent linkage is
highly stable until the antibody-drug conjugate enters
lysosomal vesicles, which allows for drug release in the
cytoplasm and the disruption of microtubule polymeriza-
tion (29–31). In addition to endometrial cancer, MEDI-
547 was previously reported to effectively inhibit the
growth of human prostate cancer xenografts (12).
We have recently reported the use of a novel orthotopic
model for uterine cancer that recapitulates the pattern of
spread seen in endometrial cancer patients (15). A major
drawback of using s.c. xenograft models is that the micro-
environment is quite different compared with tumors
grown in the native organ (32, 33). In the current study,www.aacrjournals.org
Researc
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or Ishikawa cells. Following tumor growth within the uter-
us, there was spread to multiple locations in the abdomi-
nal cavity. MEDI-547 treatment was effective in reducing
metastatic spread as well as primary tumor and total
tumor weight (Fig. 4).
EphA2 protein has been reported to be overexpressed in
∼50% of ovarian, prostate, colon, and brain cancers (34).
Whereas the expression of EphA2 receptor in human can-
cer has been well established, little is known about the
normal adult tissue expression and function (12). Imaging
studies using a radiolabeled version of the highly selective
anti-EphA2 antibody 1C1, revealed preferential distribu-
tion to tumors with no accumulation in any normal
mouse or rat normal tissues (35), suggesting that targeting
of the MEDI-547 to normal mouse tissues is minimal.
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